Scarica l'app Stockscreener
6.85
4.26%
0.28
Pre-mercato:
6.77
-0.08
-1.17%
Precedente Chiudi:
$6.57
Aprire:
$6.54
Volume 24 ore:
637.62K
Relative Volume:
0.62
Capitalizzazione di mercato:
$319.91M
Reddito:
$20.72M
Utile/perdita netta:
$-100.84M
Rapporto P/E:
-2.5752
EPS:
-2.66
Flusso di cassa netto:
$-78.56M
1 W Prestazione:
+2.70%
1M Prestazione:
+62.32%
6M Prestazione:
+46.68%
1 anno Prestazione:
-55.29%
Intervallo 1D:
$6.514
$7.12
Intervallo di 1 settimana:
$6.35
$7.59
Portata 52W:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Nome
4 D Molecular Therapeutics Inc
Settore
Industria
Telefono
(510) 505-2680
Indirizzo
5858 HORTON STREET #455, EMERYVILLE
Confronta FDMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
6.85 | 339.53M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Iniziato | Morgan Stanley | Underweight |
| 2024-09-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Iniziato | Barclays | Overweight |
| 2024-02-07 | Ripresa | Goldman | Buy |
| 2023-10-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-01-30 | Iniziato | BMO Capital Markets | Outperform |
| 2022-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-12 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Iniziato | Jefferies | Buy |
| 2022-01-04 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | BofA Securities | Buy |
| 2021-01-05 | Iniziato | Evercore ISI | Outperform |
| 2021-01-05 | Iniziato | Goldman | Neutral |
Mostra tutto
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
What institutional flow reveals about 4D Molecular Therapeutics Inc.2025 Dividend Review & Verified Entry Point Detection - Newser
What indicators show strength in 4D Molecular Therapeutics Inc.July 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
Price momentum metrics for 4D Molecular Therapeutics Inc. explainedMarket Volume Summary & Weekly High Conviction Ideas - Newser
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.Weekly Market Outlook & Weekly High Return Stock Opportunities - Newser
4D Molecular Therapeutics Inc. stock chart pattern explained2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Relief Rally in 4D Molecular Therapeutics Inc. Stock — Can It Hold2025 Market WrapUp & Free Daily Entry Point Trade Alerts - newsyoung.net
Candlestick Signal Suggests Reversal in 4D Molecular Therapeutics Inc.Analyst Downgrade & Weekly Watchlist of Top Performers - 선데이타임즈
Predicting 4D Molecular Therapeutics Inc. trend using moving averagesPortfolio Performance Summary & Growth Focused Investment Plans - Newser
Market reaction to 4D Molecular Therapeutics Inc.’s recent news2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
How to escape a deep drawdown in 4D Molecular Therapeutics Inc.Weekly Earnings Recap & Community Verified Trade Signals - Newser
Volatility clustering patterns for 4D Molecular Therapeutics Inc.2025 Performance Recap & Comprehensive Market Scan Insights - Newser
Is 4D Molecular Therapeutics Inc. meeting your algorithmic filter criteriaTrade Analysis Report & Risk Managed Trade Strategies - Newser
4D Molecular Therapeutics Inc. stock prediction for this weekWeekly Trade Analysis & Reliable Intraday Trade Alerts - Newser
Can trapped investors hope for a rebound in 4D Molecular Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - Newser
Is 4D Molecular Therapeutics Inc. forming a reversal patternJuly 2025 Movers & High Conviction Trade Alerts - Newser
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attention - Newser
Will 4D Molecular Therapeutics Inc. price bounce be sustainableJuly 2025 Levels & Low Risk Entry Point Guides - Newser
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $38.00 at Roth Capital - MarketBeat
4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape - MSN
4D Molecular Therapeutics Advances Clinical Programs in Q2 2025 - TipRanks
58,900 RSUs Awarded: 4D Molecular Therapeutics Strengthens Team with New Employee Inducement Grants - Stock Titan
Chardan Capital Maintains "Buy" Rating for 4D Molecular Therapeutics with $25 Target - AInvest
Advanced analytics toolkit walkthrough for 4D Molecular Therapeutics Inc.Weekly Trade Review & Daily Chart Pattern Signal Reports - Newser
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
What is HC Wainwright’s Estimate for FDMT Q3 Earnings? - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability hurdles - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $38.00 by Analysts at Roth Capital - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Receives “Buy” Rating from Chardan Capital - Defense World
Can you recover from losses in 4D Molecular Therapeutics Inc.Risk Aware Trading Ideas with Alert Levels - Newser
What makes 4D Molecular Therapeutics Inc. stock price move sharplyRisk Aware Trading Ideas with Alert Levels - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityHigh Return Strategy with Low Risk - Newser
4D Molecular: Roth Capital Maintains Buy, PT Down to $38 from $44 - AInvest
Using AI based signals to follow 4D Molecular Therapeutics Inc.Consistent Gain Plan with AI Support - Newser
Chardan Capital Raises PT on 4D Molecular to $25. - AInvest
Published on: 2025-08-12 01:26:37 - Newser
Will earnings trigger a reversal in 4D Molecular Therapeutics Inc.Free Pattern Breakout Entry Stock Forecast - Newser
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
4D Molecular Therapeutics Tightens Belt While Chasing FDA Approval - Finimize
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Spectral Ai, Inc. shares rise 1.64% premarket after 4D Molecular Therapeutics reported positive 60-week results from 4D-150 SPECTRA clinical trial in DME. - AInvest
4 D Molecular Therapeutics Inc Azioni (FDMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4 D Molecular Therapeutics Inc Azioni (FDMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer |
Sep 16 '24 |
Sale |
16.33 |
500 |
8,165 |
6,781 |
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):